Locoregional Management of Hepatic Metastasis From Primary Uveal Melanoma

Seminars in Oncology

Volumn 37, Issue 2, 2010, Pages 127-138

  Sato, Takami ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETHIODIZED OIL; FOTEMUSTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; INTERLEUKIN 2; IRINOTECAN; MELPHALAN; MITOMYCIN C; PLATINUM DERIVATIVE; TUMOR NECROSIS FACTOR;

ABDOMINAL PAIN; ARTERY PERFUSION; ARTICLE; ARTIFICIAL EMBOLISM; BILOBAR DISEASE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM ULCER; DRUG ELUTING BEAD; DRUG MEGADOSE; ECHOGRAPHY; GASTROINTESTINAL DISEASE; HEPATIC ARTERY; HUMAN; IMMUNOEMBOLIZATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; LIVER DISEASE; LIVER METASTASIS; LIVER TOXICITY; METASTASIS POTENTIAL; MORBIDITY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARALYTIC ILEUS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; SAFETY; SELECTIVE INTERNAL RADIATION THERAPY; TREATMENT RESPONSE; UVEA MELANOMA; VEIN OCCLUSION;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EMBOLIZATION, THERAPEUTIC; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MELANOMA; RADIOTHERAPY; UVEAL NEOPLASMS;

EID: 77952391404     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.03.014     Document Type: Article

References (75)

1. Strickland D., and Lee J.A. Melanomas of eye: stability of rates. Am J Epidemiol 113 (1981) 700-702
2. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS report no. 1. Arch Ophthalmol 108 (1990) 1268-1273
3. Kujala E., Makitie T., and Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 44 (2003) 4651-4659
4. Singh A.D., and Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 110 (2003) 962-965
5. Rajpal S., Moore R., and Karakousis C.P. Survival in metastatic ocular melanoma. Cancer 52 (1983) 334-336
6. Char D.H. Metastatic choroidal melanoma. Am J Ophthalmol 86 (1978) 76-80
7. Einhorn L.H., Burgess M.A., and Gottlieb J.A. Metastatic patterns of choroidal melanoma. Cancer 34 (1974) 1001-1004
8. Albert D.M., Ryan L.M., and Borden E.C. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol 114 (1996) 107-108
9. Bedikian A.Y., Legha S.S., Mavligit G., et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 76 (1995) 1665-1670
10. Bedikian A.Y. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin 46 (2006) 151-166
11. Singh A.D., Shields C.L., and Shields J.A. Prognostic factors in uveal melanoma. Melanoma Res 11 (2001) 255-263
12. Becher R., Korn W.M., and Prescher G. Use of fluorescence in situ hybridization and comparative genomic hybridization in the cytogenetic analysis of testicular germ cell tumors and uveal melanomas. Cancer Genet Cytogenet 93 (1997) 22-28
13. Prescher G., Bornfeld N., Hirche H., Horsthemke B., Jockel K.H., and Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347 (1996) 1222-1225
14. Sisley K., Parsons M.A., Garnham J., et al. Association of specific chromosome alterations with tumour phenotype in posterior uveal melanoma. Br J Cancer 82 (2000) 330-338
15. Gombos D.S., Van Quill K.R., Uusitalo M., and O'Brien J.M. Geographic disparities in diagnostic screening for metastatic uveal melanoma. Ophthalmology 111 (2004) 2254-2258
16. Diener-West M., Reynolds S.M., Agugliaro D.J., et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol 22 (2004) 2438-2444
17. Eskelin S., Pyrhonen S., Summanen P., Prause J.U., and Kivela T. Screening for metastatic malignant melanoma of the uvea revisited. Cancer 85 (1999) 1151-1159
18. Aoyama T., Mastrangelo M.J., Berd D., et al. Protracted survival after resection of metastatic uveal melanoma. Cancer 89 (2000) 1561-1568
19. Hsueh E.C., Essner R., Foshag L.J., Ye X., Wang H.J., and Morton D.L. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer 100 (2004) 122-129
20. Fournier G.A., Albert D.M., Arrigg C.A., Cohen A.M., Lamping K.A., and Seddon J.M. Resection of solitary metastasis. Approach to palliative treatment of hepatic involvement with choroidal melanoma. Arch Ophthalmol 102 (1984) 80-82
21. Salmon R.J., Levy C., Plancher C., et al. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol 24 (1998) 127-130
22. Curley S.A., Izzo F., Delrio P., et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 230 (1999) 1-8
23. Lieberman S., Goldin E., Lotem M., and Bloom A.I. Irrigation of the bile ducts with chilled saline during percutaneous radiofrequency ablation of a hepatic ocular melanoma metastasis. Am J Roentgenol 183 (2004) 596-598
24. Pawlik T.M., Izzo F., Cohen D.S., Morris J.S., and Curley S.A. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 10 (2003) 1059-1069
25. Peng Z.W., Chen M.S., Liang H.H., et al. A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol 36 (2009) 257-263
26. Takaki H., Yamakado K., Uraki J., et al. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm. J Vasc Interv Radiol 20 (2009) 217-224
27. Ensminger W.D., and Gyves J.W. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 10 (1983) 176-182
28. Collins J.M. Pharmacologic rationale for regional drug delivery. J Clin Oncol 2 (1984) 498-504
29. Eksborg S., Cedermark B.J., and Strandler H.S. Intrahepatic and intravenous administration of Adriamycin-a comparative pharmacokinetic study in patients with malignant liver tumours. Med Oncol Tumor Pharmacother 2 (1985) 47-54
30. Breedis C., and Young G. The blood supply of neoplasms in the liver. Am J Pathol 30 (1954) 969-977
31. Lien W.M., and Ackerman N.B. The blood supply of experimental liver metastases. II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber. Surgery 68 (1970) 334-340
32. Ackerman N.B., Lien W.M., and Silverman N.A. The blood supply of experimental liver metastases. 3. The effects of acute ligation of the hepatic artery or portal vein. Surgery 71 (1972) 636-641
33. Sigurdson E.R., Ridge J.A., Kemeny N., and Daly J.M. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 5 (1987) 1836-1840
34. Patel S., Tuite C.M., Mondschein J.I., and Soulen M.C. Effectiveness of an aggressive antibiotic regimen for chemoembolization in patients with previous biliary intervention. J Vasc Interv Radiol 17 (2006) 1931-1934
35. Sharma K.V., Gould J.E., Harbour J.W., et al. Hepatic arterial chemoembolization for management of metastatic melanoma. Am J Roentgenol 190 (2008) 99-104
36. Vogl T., Eichler K., Zangos S., et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol 133 (2007) 177-184
37. Patel K., Sullivan K., Berd D., et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 15 (2005) 297-304
38. Huppert P.E., Fierlbeck G., Pereira P., et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol (2009 May 19) (Epub ahead of print)
39. Mavligit G.M., Charnsangavej C., Carrasco C.H., Patt Y.Z., Benjamin R.S., and Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 260 (1988) 974-976
40. Sato T., Nathan F.E., Berd D., et al. Lacks of effects from chemoembolization for liver metastases from uveal melanoma [abstract]. Proc Am Soc Clin Oncol 14 (1995) 415
41. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
42. Carrasco C.H., Wallace S., Charnsangavej C., Papadopoulos N.E., Patt Y.Z., and Mavligit G.M. Treatment of hepatic metastases in ocular melanoma. Embolization of the hepatic artery with polyvinyl sponge and cisplatin. JAMA 255 (1986) 3152-3154
43. Dayani P.N., Gould J.E., Brown D.B., Sharma K.V., Linette G.P., and Harbour J.W. Hepatic metastasis from uveal melanoma: angiographic pattern predictive of survival after hepatic arterial chemoembolization. Arch Ophthalmol 127 (2009) 628-632
44. Fujita T., Ito K., Tanabe M., Yamatogi S., Sasai H., and Matsunaga N. Iodized oil accumulation in hypervascular hepatocellular carcinoma after transcatheter arterial chemoembolization: comparison of imaging findings with CT during hepatic arteriography. J Vasc Interv Radiol 19 (2008) 333-341
45. Grabstein K.H., Urdal D.L., Tushinski R.J., et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232 (1986) 506-508
46. Soiffer R., Hodi F.S., Haluska F., et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21 (2003) 3343-3350
47. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90 (1993) 3539-3543
48. Smith P.D., Lamerson C.L., Wong H.L., Wahl L.M., and Wahl S.M. Granulocyte-macrophage colony-stimulating factor stimulates human monocyte accessory cell function. J Immunol 144 (1990) 3829-3834
49. Sato T., Eschelman D.J., Gonsalves C.F., et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 26 (2008) 5436-5442
50. Yamamoto A., Chervoneva I., Sullivan K.L., et al. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology 252 (2009) 290-298
51. 90Y-microspheres. J Nucl Med 41 (2000) 1673-1681
52. Lau W.Y., Leung W.T., Ho S., et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 70 (1994) 994-999
53. 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16 (2005) 1627-1639
54. Gray B., Van Hazel G., Hope M., et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12 (2001) 1711-1720
55. Kennedy A.S., Coldwell D., Nutting C., et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65 (2006) 412-425
56. 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31 (2008) 271-279
57. Salem R., and Thurston K.G. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol 17 (2006) 1571-1593
58. Gonsalves C, Sullivan KL, Eschelman DJ, et al. Treatment of melanoma liver metastases using Y-90 SIR-Spheres: imaging and clinical response [abstract]. Annual Meeting of SIR. Washington, DC; March 15-20, 2008.
59. Kennedy A.S., Nutting C., Jakobs T., et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 27 (2009) 682-690
60. Poon R.T., Tso W.K., Pang R.W., et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5 (2007) 1100-1108
61. Varela M., Real M.I., Burrel M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46 (2007) 474-481
62. Fiorentini G., Aliberti C., Turrisi G., et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo 21 (2007) 1085-1091
63. Leyvraz S., Spataro V., Bauer J., et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 15 (1997) 2589-2595
64. Peters S., Voelter V., Zografos L., et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 17 (2006) 578-583
65. Siegel R., Hauschild A., Kettelhack C., Kahler K.C., Bembenek A., and Schlag P.M. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol 33 (2007) 627-632
66. Becker J.C., Terheyden P., Kampgen E., et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 87 (2002) 840-845
67. Cantore M., Fiorentini G., Aitini E., et al. Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver. Report of a phase II study. Tumori 80 (1994) 37-39
68. Alexander H.R., Libutti S.K., Bartlett D.L., Puhlmann M., Fraker D.L., and Bachenheimer L.C. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 6 (2000) 3062-3070
69. Alexander Jr. H.R., Libutti S.K., Pingpank J.F., et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 9 (2003) 6343-6349
70. Farma J.M., Pingpank J.F., and Alexander H.R. Isolated hepatic perfusion: treating unresectable liver metastases. Adv Exp Med Biol 574 (2006) 1-16
71. Feldman E.D., Pingpank J.F., and Alexander Jr. H.R. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 11 (2004) 290-297
72. van Iersel L.B., Hoekman E.J., Gelderblom H., et al. Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann Surg Oncol 15 (2008) 1891-1898
73. Noter S.L., Rothbarth J., Pijl M.E., et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res 14 (2004) 67-72
74. Miao N., Pingpank J.F., Alexander H.R., Steinberg S.M., Beresneva T., and Quezado Z.M. Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations. Ann Surg Oncol 15 (2008) 815-823
75. PingPank J.F. Hyperthermic isolated hepatic perfusion (IHP) using melphalan for patients with ocular melanoma metastatic to the liver. Proceedings of Perspectives in Melanoma VII (2004) 117-125